©IDOSR PUBLICATIONS

ISSN: 2550-794X

International Digital Organization for Scientific Research
IDOSR JOURNAL OF SCIENTIFIC RESEARCH 9(3)1-7, 2024.
https://doi.org/10.59298/IDOSRJSR/2024/9.3.17.100

IDOSRJSR9.3.17100

The Impact of Gut Microbiome on Prostate Health and BPH Progression: A Comprehensive Review

Mugisha Emmanuel K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Benign Prostatic Hyperplasia (BPH) is a prevalent condition in aging men, characterized by prostate enlargement and associated lower urinary tract symptoms (LUTS). While traditional risk factors include age, hormonal imbalances, and genetics, recent research suggests that the gut microbiome may significantly influence prostate health and BPH progression. The gut microbiome, comprising trillions of microorganisms, plays a crucial role in systemic processes such as inflammation, immune modulation, and hormonal regulation, all of which are implicated in BPH pathogenesis. This comprehensive review explores the mechanisms linking gut dysbiosis to prostate health, with a focus on systemic inflammation, hormonal disturbances, and immune responses. Dysbiosis, or an imbalance in gut microbial communities, can lead to chronic inflammation, elevated levels of pro-inflammatory cytokines, and disruptions in androgen and estrogen metabolism, contributing to the onset and progression of BPH. Emerging evidence from both animal and human studies highlights significant differences in the gut microbiota of men with BPH compared to healthy controls, suggesting a potential role for microbiome-based interventions. Furthermore, the review discusses the therapeutic potential of probiotics, prebiotics, and dietary modifications in modulating gut health to alleviate BPH symptoms. Personalized microbiome-targeted therapies represent a promising avenue for future research. This review underscores the importance of the gut-prostate axis in understanding prostate health and suggests that targeting the gut microbiome could lead to novel strategies for preventing and managing BPH.

Keywords: Gut microbiome, Prostate health, Benign Prostatic Hyperplasia, Urinary tract symptoms, Dysbiosis

INTRODUCTION

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, a condition that commonly affects men as they age [1]. This prostate enlargement often results in lower urinary tract symptoms (LUTS) such as increased urinary frequency, urgency, weak stream, and nocturia, significantly impairing the quality of life for affected individuals [2]. The global prevalence of BPH increases with age, affecting approximately 50% of men in their 50s and up to 90% of men aged 80 and above. While the exact cause of BPH remains elusive, several well-established risk factors contribute to its development, including age-related hormonal changes, genetics, and lifestyle factors [3,4]. Historically, the primary drivers of BPH have been attributed to hormonal imbalances, particularly involving androgens like testosterone and dihydrotestosterone (DHT), as well as estrogen. These hormones regulate prostate growth, and their dysregulation with age has been strongly linked to prostatic hyperplasia [5,6]. Chronic inflammation is another key factor that contributes to prostate enlargement [7]. Research has shown that immune

cells, including macrophages and T-cells, infiltrate the prostate in response to cellular damage or infections, promoting tissue remodeling and hyperplasia [8]. Although hormonal regulation and inflammation remain central to understanding BPH pathophysiology, recent scientific advances have prompted researchers to explore other potential contributing factors. In the past decade, there has been growing interest in the role of the gut microbiome in regulating various systemic processes, including metabolism, immunity, and inflammation. The gut microbiome refers to the trillions of microorganisms, including bacteria, viruses, fungi, and archaea, that reside within the gastrointestinal tract [9]. These microbes are not merely passive passengers but are actively involved in numerous physiological processes. They assist in digesting food, synthesizing essential vitamins, regulating immune responses, and producing metabolites that affect distant organs [10]. Emerging evidence suggests that the gut microbiome may play a crucial role in diseases beyond the gastrointestinal tract, influencing conditions such as cardiovascular disease, obesity, diabetes, and even neurological disorders [11].

Recently, researchers have begun investigating the potential relationship between the gut microbiome and prostate health, including its impact on BPH. This connection, often referred to as the "gut-prostate axis," proposes that the gut microbiome can influence prostate health through various mechanisms, such as modulating systemic inflammation, regulating hormone levels, and shaping immune responses [12]. Dysbiosis, or an imbalance in the gut microbial population, can lead to increased intestinal permeability, allowing bacterial endotoxins and metabolites to enter the bloodstream and contribute to chronic inflammation [13]. This low-grade, systemic inflammation may reach the prostate and exacerbate prostatic hyperplasia and other pathological changes. While the exact pathways linking the gut microbiome and prostate health are still under investigation, several studies have provided compelling evidence that gut microbiota alterations are associated with BPH development and progression [14]. Moreover, gut microbiota may impact hormonal regulation by metabolizing androgens and estrogens, further contributing to BPH pathogenesis [15]. As a result, there is growing interest in exploring microbiome-based therapeutic interventions, such as probiotics, prebiotics, and dietary modifications, to potentially prevent or mitigate BPH progression. This review aims to explore the emerging relationship between the gut microbiome and prostate health, with a specific focus on BPH. It synthesizes current research on the mechanisms by which the gut microbiome may influence prostate inflammation, hormonal balance, and immune modulation. Additionally, this review will discuss the potential for microbiome-targeted therapies as novel approaches for BPH management and highlight areas for future research in this promising field.

Overview of BPH: Pathophysiology and Risk Factors

Pathophysiology of BPH

BPH is characterized by the proliferation of epithelial and stromal cells within the prostate, leading to the enlargement of the gland. This can compress the urethra, resulting in lower urinary tract symptoms (LUTS), including difficulty in urination, increased frequency, and nocturia [16,17]. The primary contributing factors to BPH include hormonal imbalances (such as changes in testosterone and estrogen levels), inflammatory processes, and cellular senescence [18]. Chronic inflammation is increasingly recognized as a significant driver in the pathogenesis of BPH, contributing to tissue remodeling, fibrosis, and prostatic hyperplasia [19,20].

Traditional Risk Factors

1. **Age:** The likelihood of developing BPH increases with age, affecting around 50% of men in their 50s and nearly 90% in men over 80[21].
2. **Hormonal Changes:** Androgens like testosterone and its more active form, dihydrotestosterone (DHT), are central to prostate growth. Estrogens also play a role by promoting stromal and epithelial cell proliferation [22].
3. **Genetics:** Family history of BPH increases the risk of developing the condition [23].

Lifestyle and Diet: Diets rich in red meat, high-fat content, and low in fiber have been associated with an increased risk of BPH [24].

The Gut Microbiome: A Crucial Player in Human Health

Gut Microbiome Composition

The gut microbiome consists of a vast and diverse population of bacteria, archaea, fungi, viruses, and other microbes. These microbes contribute to various physiological processes, including the digestion of food, synthesis of vitamins, modulation of the immune system, and protection against pathogens [11,25]. Notably, gut microbiota can influence systemic inflammation and hormonal regulation two factors closely tied to BPH pathogenesis.

Dysbiosis: Imbalance in Microbial Communities

Dysbiosis refers to an imbalance in the gut microbial ecosystem, where harmful bacteria may outnumber beneficial species. This imbalance can lead to increased intestinal permeability (commonly referred to as "leaky gut"), allowing bacterial metabolites and toxins to enter the bloodstream [26]. These endotoxins can promote systemic inflammation and immune responses, which have been implicated in several chronic conditions, including cardiovascular diseases, diabetes, and prostate disorders like BPH [27].

Gut Microbiome and Prostate Health: Mechanistic Insights

Systemic Inflammation and Prostate Health

One of the primary mechanisms linking gut health to prostate conditions, including BPH, is inflammation. Dysbiosis can lead to the production of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which have been associated with prostate inflammation and hyperplasia [28]. Chronic low-grade inflammation in the gut can trigger similar responses in the prostate, leading to the onset and progression of BPH. Some studies suggest that bacterial metabolites, such as lipopolysaccharides (LPS), which enter the bloodstream from the gut, may exacerbate prostatic inflammation and drive cellular proliferation in the prostate [29].

Hormonal Regulation and the Microbiome

The gut microbiome plays a crucial role in regulating hormone levels, particularly through the metabolism of androgens and estrogens [30]. For instance, certain bacterial species possess the ability to convert testosterone into its more potent form, DHT, which is directly linked to prostate enlargement [31]. Additionally, gut bacteria influence the enterohepatic circulation of estrogens, which can affect the hormonal balance within the prostate [32]. Disruptions in these microbiome-mediated pathways may contribute to the hormonal imbalances that underlie BPH.

Immune Modulation

The gut microbiome influences both local and systemic immunity. Regulatory T cells (Tregs), produced under the influence of specific gut microbes, help maintain immune tolerance and control inflammatory responses [33]. In individuals with BPH, there is evidence of altered immune responses, with increased infiltration of immune cells into the prostate [34]. The gut microbiome may modulate these immune dynamics by influencing the recruitment and activity of immune cells, potentially exacerbating or mitigating inflammation within the prostate [35].

Gut Dysbiosis and BPH Progression

Animal and Human Studies

Several animal studies have demonstrated the link between gut microbiota and prostate conditions. For example, mouse models with altered gut microbiomes have shown increased susceptibility to prostatic inflammation and hyperplasia [36]. In humans, studies comparing the gut microbiota of men with BPH and healthy controls have identified significant differences in microbial composition. Specifically, men with BPH tend to have reduced levels of beneficial bacteria such as Lactobacillus and Bifidobacterium, which are known for their anti-inflammatory properties, and higher levels of pro-inflammatory bacteria like Escherichia coli and Enterococcus [37,38].

Role of Diet and Probiotics

Diet plays a pivotal role in shaping the gut microbiome, and dietary interventions may offer a pathway to modulate prostate health. Diets rich in fiber, plant-based foods, and omega-3 fatty acids have been shown to support a healthy gut microbiome, reduce systemic inflammation, and potentially lower the risk of BPH [39]. Probiotics and prebiotics, which help restore microbial balance, are also being investigated as potential therapeutic options to alleviate BPH symptoms by reducing

inflammation and supporting hormonal regulation [40].

Therapeutic Implications and Future Directions

Microbiome-Based Therapies

Given the emerging evidence linking the gut microbiome to prostate health, microbiome-based therapies, including probiotics, prebiotics, and fecal microbiota transplantation (FMT), hold promise for BPH management [41]. Probiotics, particularly strains of Lactobacillus and Bifidobacterium, may help restore microbial balance, reduce systemic inflammation, and alleviate BPH symptoms [40].

Precision Medicine Approach

Personalized medicine approaches that consider an individual's gut microbiome composition could lead to more effective BPH treatments. By tailoring interventions based on microbiome profiles, clinicians may be able to identify individuals who are more likely to benefit from dietary modifications, probiotic supplementation, or microbiome-targeted therapies [42, 43].

Future Research Directions

Future research should focus on longitudinal studies to establish causal links between gut microbiota and BPH progression. Understanding the specific microbial species and metabolic pathways involved in prostate inflammation and hyperplasia will be essential to developing targeted microbiome-based interventions. Additionally, investigating the gut-prostate axis in diverse populations will help identify whether certain microbial patterns are universally associated with BPH or vary based on genetic, lifestyle, and environmental factors.

CONCLUSION

The gut microbiome represents a novel and promising area of research in understanding prostate health and the progression of BPH. Current evidence suggests that gut dysbiosis can influence systemic inflammation, hormonal regulation, and immune responses, all of which contribute to the development and progression of BPH. Although more research is needed to fully elucidate the mechanisms involved, the potential for microbiome-based therapies offers an exciting new avenue for the prevention and treatment of BPH. As our understanding of the gut-prostate axis deepens, it may revolutionize the way we approach prostate health and age-related conditions like BPH. This comprehensive review highlights the emerging connection between gut microbiota and prostate health, suggesting that future therapies targeting the microbiome could play a pivotal role in managing BPH and promoting overall prostate well-being.

REFERENCES

1. Kamyar M. Hedayat, Jean-Claude Lapraz, Chapter 7 - Disorders of the prostate: Lower urinary tract obstruction and prostatitis, Editor(s): Kamyar M. Hedayat, Jean-Claude Lapraz, The Theory of Endobiogeny, Academic Press, 2019; 135-164. https://doi.org/10.1016/B978-0-12-816964-3.00007-9.
2. Adediran AO, Olatunbosun EI. A descriptive study of prostate lesions in largest hospital In Ondo State of Nigeria. Global Journal of Health Sciences. 2020 Sep 10;5(2):18-39.
3. Beland L, Martin C, Han JS. Lower urinary tract symptoms in young men—causes and management. Current Urology Reports. 2022 Feb;23(2):29-37.
4. Uroko Robert Ikechukwu, Fatima Amin Adamude, Egba Simeon Ikechukwu, Chinedu Paulinus Nwuke, Chidinma Lilian Asadu and Peter Anyaorah. Effect of combined ethanol extract of Funtumia Africana and Abutilon mauritanium leaves on prostate biomarkers and serum mineral levels in prostatic hyperplasia induced in rats. J. Renal Endocrinol 2021; 7:e06
5. Ng M, Leslie SW, Baradhi KM. Benign prostatic hyperplasia. StatPearls [Internet]. 2024 Jan 11.
6. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011 Nov 1;82(4-5):184-99.

7. Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. Endocrinology of the aging prostate: current concepts. Frontiers in Endocrinology. 2021 Feb 22;12:554078.

8. Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia–what do we know?. BJU international. 2021 Apr;127(4):389-99.

9. Cao D, Sun R, Peng L, Li J, Huang Y, Chen Z, Chen B, Li J, Ai J, Yang L, Liu L. Immune cell proinflammatory microenvironment and androgen-related metabolic regulation during benign prostatic hyperplasia in aging. Frontiers in Immunology. 2022 Mar 21;13:842008.

10. Ahmed U, Khan F. Understanding. The Gut Microbiome: Implications For Human Health. The Research of Medical Science Review. 2023 Jun 30;1(01):47-56.

11. Vernocchi P, Del Chierico F, Putignani L. Gut microbiota metabolism and interaction with food components. International Journal of Molecular Sciences. 2020 May 23;21(10):3688.

12. Durack J, Lynch SV. The gut microbiome: Relationships with disease and opportunities for therapy. Journal of experimental medicine. 2019 Jan 7;216(1):20-40.

13. Fujita K, Matsushita M, De Velasco MA, Hatano K, Minami T, Nonomura N, Uemura H. The gut-prostate axis: a new perspective of prostate cancer biology through the gut microbiome. Cancers. 2023 Feb 21;15(5):1375.

14. Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Internal and emergency medicine. 2024 Mar;19(2):275-93.

15. Li LY, Han J, Wu L, Fang C, Li WG, Gu JM, Deng T, Qin CJ, Nie JY, Zeng XT. Alterations of gut microbiota diversity, composition and metabonomics in testosterone-induced benign prostatic hyperplasia rats. Military Medical Research. 2022 Mar 28;9(1):12.

16. Yang Y, Quan Y, Liu Y, Yang J, Chen K, You X, Hua H, Yan L, Zhao J, Wang J. Exploring the potential mechanism of Xiaojin Pill therapy for benign prostatic hyperplasia through metabolomics and gut microbiota analysis. Frontiers in Microbiology. 2024 Aug 21;15:1431954.

17. Shapur SR. *The Study of Prostate Specific Antigen and Prostate Volume in Benign Prostatic Hyperplasia* (Master's thesis, Rajiv Gandhi University of Health Sciences (India)).

18. Yuan YF, Zhu WX, Liu T, He JQ, Zhou Q, Zhou X, Zhang X, Yang J. Cyclopamine functions as a suppressor of benign prostatic hyperplasia by inhibiting epithelial and stromal cell proliferation via suppression of the Hedgehog signaling pathway. International Journal of Molecular Medicine. 2020 Jul;46(1):311-9.

19. IR Uroko, F A Adamude, S I Egba, C N Chukwu, C L Asadu, E C Okwara. Effects of combined ethanol extract of *Funtumia africana* and *Abutilon mauritianum* leaves (FAAM) on liver function indices of benign prostatic hyperplasia (BPH) induced rats, *Herba Polonica,2020;* 66 (3): 24-35

20. Inamura S, Terada N. Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options. International Journal of Urology. 2024 Jun 27.

21. Russo GI, Urzì D, Cimino S. Epidemiology of LUTS and BPH. InLower Urinary Tract Symptoms and Benign Prostatic Hyperplasia 2018 Jan 1 (pp. 1-14). Academic Press.

22. Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumbikat P, Hayward SW. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review.

Asian journal of urology. 2020 Jul 1;7(3):191-202.

23. 23 Robert I. Uroko., Charles N. Chukwu., Simeon I. Egba1., Fatima A. Adamude andJoy C. Ajuzie. Combined ethanol extract of *Funtumia africana* and *Abutilon mauritianium* leaves improves the lipid profile and kidney function indices of benign prostatic hyperplasia in rats. *Acta Sci. Pol. Technol. Aliment.* 2020; 19(4): 395-4045

24. Casals R, Badalato G, Rutman M. Role of diet in the development and progression of benign prostatic hyperplasia. InMolecular Mechanisms of Nutritional Interventions and Supplements for the Management of Sexual Dysfunction and Benign Prostatic Hyperplasia 2021 Jan 1 (pp. 81-94). Academic Press.

25. Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020 Dec;113(12):2019-40.

26. Belizário JE, Faintuch J. Microbiome and gut dysbiosis. InMetabolic interaction in infection 2018 Apr 7 (pp. 459-476). Cham: Springer International Publishing.

27. Matsushita M, Fujita K, Hatano K, De Velasco MA, Tsujimura A, Uemura H, Nonomura N. Emerging relationship between the gut microbiome and prostate cancer. The World Journal of Men's Health. 2023 Oct;41(4):759.

28. Friedrich V, Choi HW. The urinary microbiome: role in bladder cancer and treatment. Diagnostics. 2022 Aug 26;12(9):2068.

29. Hughes Jr FM, Odom MR, Cervantes A, Livingston AJ, Purves JT. Why are some people with lower urinary tract symptoms (LUTS) depressed? New evidence that peripheral inflammation in the bladder causes central inflammation and mood disorders. International journal of molecular sciences. 2023 Feb 1;24(3):2821.

30. Qi X, Yun C, Pang Y, Qiao J. The impact of the gut microbiota on the reproductive and metabolic endocrine system. Gut microbes. 2021 Jan 1;13(1):1894070.

31. Pernigoni N, Guo C, Gallagher L, Yuan W, Colucci M, Troiani M, Liu L, Maraccani L, Guccini I, Migliorini D, de Bono J. The potential role of the microbiota in prostate cancer pathogenesis and treatment. Nature Reviews Urology. 2023 Dec;20(12):706-18.

32. Li X, Cheng W, Shang H, Wei H, Deng C. The interplay between androgen and gut microbiota: is there a microbiota-gut-testis axis. Reproductive Sciences. 2022 Jun;29(6):1674-84.

33. Fiyouzi T, Pelaez-Prestel HF, Reyes-Manzanas R, Lafuente EM, Reche PA. Enhancing regulatory T cells to treat inflammatory and autoimmune diseases. International Journal of Molecular Sciences. 2023 Apr 25;24(9):7797.

34. Naiyila X, Li J, Huang Y, Chen B, Zhu M, Li J, Chen Z, Yang L, Ai J, Wei Q, Liu L. A novel insight into the immune-related interaction of inflammatory cytokines in Benign prostatic hyperplasia. Journal of Clinical Medicine. 2023 Feb 24;12(5):1821.

35. Li X, Zhang S, Guo G, Han J, Yu J. Gut microbiome in modulating immune checkpoint inhibitors. EBioMedicine. 2022 Aug 1;82.

36. An J, Song Y, Kim S, Kong H, Kim K. Alteration of gut microbes in benign prostatic hyperplasia model and finasteride treatment model. International Journal of Molecular Sciences. 2023 Mar 21;24(6):5904.

37. Porter CM, Shrestha E, Peiffer LB, Sfanos KS. The microbiome in prostate inflammation and prostate cancer. Prostate cancer and prostatic diseases. 2018 Sep;21(3):345-54.

38. Munteanu R, Feder RI, Onaciu A, Munteanu VC, Iuga CA, Gulei D.

Insights into the human microbiome and its connections with prostate cancer. Cancers. 2023 Apr 28;15(9):2539.

39. Kwon J, Stoddard MD, Chughtai B. Western diet and benign prostatic hyperplasia. InMolecular Mechanisms of Nutritional Interventions and Supplements for the Management of Sexual Dysfunction and Benign Prostatic Hyperplasia 2021 Jan 1 (pp. 149-165). Academic Press.

40. Chen J, Chen B, Lin B, Huang Y, Li J, Li J, Chen Z, Wang P, Ran B, Yang J, Huang H. The role of gut microbiota in prostate inflammation and benign prostatic hyperplasia and its therapeutic implications. Heliyon. 2024 Sep 21.

41. Bajaj JS, Ng SC, Schnabl B. Promises of microbiome-based therapies. Journal of hepatology. 2022 Jun 1;76(6):1379-91.

42. De Filippis F, Vitaglione P, Cuomo R, BerniCanani R, Ercolini D. Dietary interventions to modulate the gut microbiome—how far away are we from precision medicine. Inflammatory bowel diseases. 2018 Sep 15;24(10):2142-54.

43. Ugwu OP, Alum EU, Okon MB, Obeagu EI. Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. *Medicine (Baltimore)*. 2024; 103(19):e38088. doi:10.1097/MD.0000000000038088

CITE AS: Mugisha Emmanuel K. (2024). The Impact of Gut Microbiome on Prostate Health and BPH Progression: A Comprehensive Review. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 9(3)1-7. https://doi.org/10.59298/IDOSRJSR/2024/9.3.17.100